What TRT Monitoring Blood Work Should Include And Why

TRT monitoring blood work is a panel of laboratory tests drawn at timed intervals during testosterone replacement therapy to help assess whether a prescribed dose is producing the intended clinical response and to screen for known adverse effects. For men with diagnosed hypogonadism on testosterone, these labs measure total testosterone, hematocrit (red blood cell concentration), prostate-specific antigen (PSA), and metabolic markers at scheduled checkpoints. The Endocrine Society's 2018 clinical practice guideline recommends measuring hematocrit at baseline and again with testosterone at 3 to 6 months after starting therapy, then annually once levels stabilize (Bhasin et al., 2018). The AUA sets a comparable cadence, with testosterone checked after an appropriate interval and then every 6 to 12 months (Mulhall et al., 2018). A telehealth lab testing provider can make this monitoring accessible without referral delays, and the markers, timing, and interpretation all follow published clinical guidelines that every man on TRT should understand before his next draw.

TRT monitoring blood work is a set of timed laboratory tests, drawn during testosterone replacement therapy, that measures testosterone, hematocrit, PSA, estradiol, and metabolic markers to help assess whether a prescribed dose is producing the intended clinical response and to screen for erythrocytosis, prostate changes, and metabolic shifts.

What Is the Purpose of TRT Monitoring Blood Work?

TRT monitoring blood work serves 3 purposes that don't diminish over time. The first is safety surveillance. Testosterone stimulates red blood cell production, and hematocrit rises in most men on therapy. Both the Endocrine Society and the AUA identify hematocrit above 54% as a threshold at which guidelines recommend stopping or reducing the dose, based on the provider's clinical judgment (Bhasin et al., 2018; Mulhall et al., 2018). Without a blood draw, that rise is invisible until symptoms appear.

The second is dose verification. The AUA targets the middle tertile of the reference range (roughly 450-600 ng/dL) plus symptom improvement, not the highest number a lab can produce (Mulhall et al., 2018). A testosterone monitoring panel confirms whether the current dose lands in that window.

The third is metabolic tracking. Testosterone can alter lipid profiles, liver enzymes, and blood glucose. A metabolic panel (CMP) captures those changes before they compound.

This panel doesn't diagnose low testosterone. That requires a separate workup with 2 early-morning fasting draws below the guideline threshold plus signs and symptoms of hypogonadism. A pre-TRT panel covers that baseline step.

Markers in a Standard TRT Monitoring Panel

A standard TRT monitoring blood work panel includes 4 marker categories that testosterone can affect. Providers may add markers based on individual risk.

Total and free testosterone confirm whether the dose reaches a mid-normal range. Total testosterone is the primary measure. Free testosterone (the unbound fraction available to tissues) matters when total testosterone looks adequate but symptoms persist, often because high SHBG is binding most of it.

Hematocrit and CBC. A complete blood count tracks red and white blood cell counts, hemoglobin, and hematocrit. This is the safety marker most likely to change management on TRT.

PSA. Prostate-specific antigen is checked at baseline in men over 40, then periodically during the first year. The Endocrine Society recommends urology referral when confirmed PSA rises more than 1.4 ng/mL above baseline within 12 months, or when PSA exceeds 4.0 ng/mL, in men who have opted into prostate monitoring (Bhasin et al., 2018).

Estradiol. Testosterone converts to estradiol through the aromatase enzyme. The AUA recommends checking estradiol before therapy only if breast symptoms or gynecomastia are present (Expert Opinion), not on every monitoring draw (Mulhall et al., 2018). When estradiol is measured in men, LC-MS/MS (the method used in a sensitive estradiol test) avoids the cross-reactivity problems of standard immunoassays.

Metabolic panel (CMP). Liver enzymes, kidney function markers, blood glucose, and electrolytes round out the panel. Labels for FDA-approved testosterone products require periodic monitoring of these values.

Blood pressure. Following the February 2025 FDA class-wide labeling update, blood pressure monitoring is included in testosterone product labeling and should be part of routine follow-up.

The table below shows how the 2 major U.S. guidelines compare on each monitoring item.

Monitoring Marker	Endocrine Society (Bhasin et al., 2018)	AUA (Mulhall et al., 2018)
Total testosterone timing	3-6 months after start, then target mid-normal	After appropriate interval, then every 6-12 months; target middle tertile (~450-600 ng/dL)
Hematocrit threshold	Stop if >54%; evaluate hypoxia and sleep apnea; restart at lower dose	Baseline >50% delays start; on-treatment >=54% requires intervention
PSA / prostate monitoring	Assess risk at 3-12 months; urology referral if PSA rise >1.4 ng/mL or PSA >4.0	PSA in men >40 before therapy; standard screening after year 1
Estradiol	Not in routine on-treatment schedule	Only before therapy if breast symptoms or gynecomastia present
Fertility	Discuss effects on spermatogenesis before treatment	Do not prescribe exogenous T while trying to conceive (Strong, Grade A)

How Often Should Men on TRT Get Blood Work?

The Endocrine Society recommends evaluating the patient and measuring testosterone at 3 to 6 months after initiation, with hematocrit checked at baseline, at 3 to 6 months, and then annually (Bhasin et al., 2018). The AUA says to measure testosterone every 6 to 12 months while on therapy (Mulhall et al., 2018). Both guidelines recommend retesting after any dose adjustment, typically at 3 months.

PSA monitoring follows a front-loaded pattern. In men who choose prostate screening, the Endocrine Society recommends assessment before therapy, again at 3 to 12 months, and then annually using standard age- and risk-based guidelines. If symptoms haven't improved after 3 to 6 months despite a testosterone level in the target range, the AUA recommends discussing whether to continue (Mulhall et al., 2018).

Correct hormone test timing is as important as the test itself.

Scheduling and Preparing for a TRT Blood Draw

Blood should be drawn in the morning, between 7 and 10 a.m., when testosterone levels are highest. Fasting for at least 8 hours is standard; water is fine. Men taking biotin supplements (common in hair and nail products) should stop at least 72 hours before the draw, because biotin interferes with hormone immunoassays and can skew results. The FDA has flagged this interference in a safety communication.

Proper preparation for labs also means telling the provider about all current medications and supplements before the draw.

Does Draw Timing Depend on the Testosterone Formulation?

Yes, and getting it wrong produces misleading results. For injectable testosterone cypionate or enanthate, the Endocrine Society recommends measuring testosterone about 1 week after the injection (mid-interval) to capture a value closer to the average, not the peak or trough. Gel labels (such as the AndroGel 1.62% label) specify a pre-dose morning measurement at 14 and 28 days after starting, then after any dose change. For long-acting injectable undecanoate (Aveed), a pre-injection draw captures the trough. Pellet monitoring typically falls at 2 to 4 weeks and again at 10 to 12 weeks after placement. Marek Diagnostics does not offer pellet implantation.

Comparing a peak drawn 24 hours after a weekly injection to a mid-normal target may not produce a clinically meaningful comparison. The draw timing, lab, and assay should stay the same across visits so that results are comparable.

Interpreting TRT Monitoring Blood Work Results

A provider reads TRT monitoring blood work as a set, not one marker at a time, alongside symptoms, therapy history, and the formulation being used. Reference ranges differ between laboratories. A single out-of-range result doesn't automatically require a dose change.

In-Range Results on TRT

When testosterone falls within the target range, hematocrit remains in the laboratory's reference interval, and PSA is stable, the current dose is working. "In range" doesn't always mean symptoms have resolved. If fatigue or low libido persists despite a mid-normal total testosterone, the provider may check free testosterone and SHBG, evaluate thyroid function, or review medication adherence and delivery method. Knowing normal hormone levels and what shifts them helps men have an informed conversation with their provider. Routine monitoring continues on schedule.

Out-of-Range TRT Blood Work and Next Steps

Hematocrit above 54% is among the findings most likely to prompt a change in therapy. Both guidelines recommend considering a pause in therapy until hematocrit falls, along with evaluation for contributing factors like sleep apnea or hypoxia. The decision to adjust the dose, switch formulations, or pause therapy depends on the individual's full clinical picture. Stopping therapy without provider guidance is not recommended.

High estradiol with breast tenderness may prompt a dose reduction, a switch from injections to gels (which produce lower peaks and less aromatization), or more frequent smaller injections. Aromatase inhibitors carry risks of their own, including bone density loss, and are typically reserved for cases where dose or formulation changes haven't resolved the issue.

Low free testosterone with normal total testosterone usually points to high SHBG. The provider may measure SHBG directly and adjust therapy.

Abnormal CMP values (high liver enzymes, kidney function changes, or blood glucose shifts) may lead to a review of other medications, lifestyle factors, or the testosterone formulation itself. Providers can identify additional testing through individual biomarkers or lab bundles to clarify the picture.

Why Assay Standardization Matters for TRT Blood Work

The same blood sample can return different testosterone numbers at different laboratories. The CDC's Hormone Standardization (HoSt) Program certifies total testosterone assays to a precision standard of +-6.4% mean bias versus the CDC reference measurement procedure (CDC, 2026). The Endocrine Society stated in July 2026 that many testosterone assays remain inaccurate, give variable results, and rely on improper reference ranges (Endocrine Society, 2026). Labs using HoSt-certified assays can apply the clinical thresholds from the Endocrine Society guideline; labs using uncertified assays may not classify the same sample the same way.

This is why the guidelines themselves disagree on a single number. The AUA uses 300 ng/dL as a reasonable total testosterone cutoff. The Endocrine Society's harmonized threshold is 264 ng/dL on a CDC-certified assay. The EAU 2025 update uses approximately 350 ng/dL. A given result can fall below one guideline's threshold and above another's. None of these thresholds alone establishes a diagnosis; each guideline requires symptoms alongside laboratory findings, and the decision to treat is made between the individual and provider. Asking which assay and which guideline the provider follows is a question most men on TRT never ask, but it changes how their TRT monitoring blood work is interpreted.

What the TRAVERSE Trial and FDA Update Changed for TRT Monitoring

The TRAVERSE trial (5,246 men ages 45-80 with high cardiovascular risk and diagnosed hypogonadism) found that the primary cardiac endpoint (cardiovascular death, nonfatal heart attack, or nonfatal stroke) occurred at a similar rate in the testosterone group and the placebo group: 7.0% vs. 7.3% (HR 0.96; 95% CI 0.78-1.17) (Lincoff et al., 2023). That neutral finding led the FDA to remove the previous cardiovascular boxed warning from all testosterone product labels in February 2025.

TRAVERSE is not a blanket safety endorsement. The testosterone group also had higher rates of pulmonary embolism (0.9% vs. 0.5%), atrial fibrillation (3.5% vs. 2.4%), and acute kidney injury (2.3% vs. 1.5%) (Lincoff et al., 2023). These rates were observed in men with preexisting or high-risk cardiovascular disease and may not apply to all men on TRT. A separate TRAVERSE analysis found more clinical fractures on testosterone than placebo (3.50% vs. 2.46%; HR 1.43) (Snyder et al., 2024).

The February 2025 FDA class-wide labeling update added a blood-pressure warning, required TRAVERSE data on all testosterone product labels, and retained the Limitation of Use stating that safety and efficacy in men with age-related low testosterone have not been established (FDA, 2025). In June 2026, the FDA requested further updates to remove that Limitation of Use and revise prostate-cancer and BPH safety language; that process is still in progress as of September 2026 (FDA, 2026).

For TRT monitoring blood work, TRAVERSE adds prospective trial evidence supporting the existing guideline recommendation for hematocrit monitoring (the trial held hematocrit below 54% by protocol and still saw more pulmonary embolism in the testosterone arm), blood pressure monitoring (now a label requirement), and honest risk disclosure at every follow-up.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does TRT monitoring blood work include estradiol on every draw?

The AUA recommends measuring estradiol before therapy only if breast symptoms or gynecomastia are present. It isn't a required serial marker in the AUA or Endocrine Society on-treatment monitoring schedules. When estradiol is measured in men, LC-MS/MS is the accurate assay method; standard immunoassays are prone to cross-reactivity and may report higher values than LC-MS/MS methods in men.

What hematocrit level requires stopping testosterone?

The Endocrine Society and AUA both treat hematocrit above 54% as a threshold for intervention. The Endocrine Society recommends stopping testosterone until hematocrit falls, evaluating for sleep apnea and hypoxia, and restarting at a lower dose. The AUA also recommends delaying therapy if baseline hematocrit exceeds 50% until the cause is identified.

How soon after starting TRT should the first blood draw happen?

The Endocrine Society recommends 3 to 6 months. Gel labels specify pre-dose morning testosterone at 14 and 28 days after starting because gels reach steady state faster than long-interval injections. Providers using injectable cypionate or enanthate generally recheck at 6 to 12 weeks, then adjust.

Can a man's TRT blood work look normal while symptoms persist?

Yes. Total testosterone can appear adequate while free testosterone remains low because of high SHBG. The AUA recommends discussing stopping therapy after 3 to 6 months if symptoms haven't improved despite a normalized testosterone level. Other causes of persistent symptoms, such as thyroid dysfunction or poor sleep, should also be evaluated.

Does TRT cause prostate cancer?

The TRAVERSE prostate-safety companion (Bhasin et al., 2023, JAMA Network Open) found similar prostate cancer rates in the testosterone and placebo groups (0.5% vs. 0.4%). Current guidelines don't contraindicate TRT solely because of prostate cancer risk, but they do recommend PSA monitoring, with urology referral if PSA rises more than 1.4 ng/mL within 12 months or exceeds 4.0 ng/mL.

Why do testosterone results differ between labs?

Testosterone assays that haven't been certified through the CDC's HoSt program can disagree on the same sample. The Endocrine Society's 2026 statement confirmed that uncertified assays have improper reference ranges. Keeping the same lab and assay across visits makes results comparable over time.

Should men on TRT get blood work if they want children later?

The AUA recommends a reproductive evaluation before starting testosterone if future fertility matters (Moderate, Grade B) and states that exogenous testosterone should not be prescribed to men who are currently trying to conceive (Strong, Grade A). hCG, SERMs, and aromatase inhibitors are guideline-conditional alternatives when preserving fertility is the priority, but they don't guarantee spermatogenesis recovery.

Your cart is currently empty.